You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Funded Evidence-Informed Regimens

Drug and regimen monographs and information sheets for patients provide information on dosing and administering cancer treatment protocols. They are for general reference and are not meant to replace prescribing information or physician recommendations.

If you have questions about ST-QBP funding on our website, please visit our Frequently Asked Questions page.

Find enhanced Regimen Patient Information Sheets, created in collaboration with patient and family advisors.

Regimens

9 Items
Cancer Type: Hematologic, Leukemia - Chronic Myeloid (CML)     
Intent: Palliative
Funding:
Exceptional Access Program
    daSAtinib - Ph+ CML in the chronic phase, with specific criteria
Exceptional Access Program
    daSAtinib - Accelerated phase or blast phase Ph+ CML with documented resistance or intolerance to imatinib, with specific criteria
May 2019
Cancer Type: Hematologic, Leukemia - Acute Lymphoblastic (ALL)     
Intent: Curative, Palliative
Funding:
Exceptional Access Program
    daSAtinib - PH+ ALL, with specific criteria
May 2019
Cancer Type: Lung, Non-Small Cell     
Intent: Palliative
Funding:
Exceptional Access Program
    gefitinib - First-line monotherapy in locally advanced (not amenable to curative therapy) or metastatic NSCLC patients who have activating mutations of EGFR-TK, with specific criteria
Jun 2019
Cancer Type: Head and Neck     
Intent: Palliative
Drugs Used:
gefitinib (Unfunded)
Aug 2019
Cancer Type: Hematologic, Lymphoma - T-cell     
Intent: Palliative
Drugs Used:
interferon alfa-2b (Unfunded),
zidovudine (Unfunded)
Oct 2017
Cancer Type: Breast     
Intent: Palliative
Funding:
New Drug Funding Program
    Pamidronate - Metastatic Breast Cancer
Aug 2018
Cancer Type: Hematologic, Multiple Myeloma     
Intent: Palliative
Funding:
New Drug Funding Program
    Pamidronate - Plasma Cell Myeloma (with bone disease)
New Drug Funding Program
    Pamidronate - Plasma Cell Myeloma (without bone disease)
Feb 2017
Cancer Type: Breast, Central Nervous System, Endocrine, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Hematologic, Lung, Sarcoma, Skin, Unknown Primary     
Intent: Supportive Care, Palliative
Jan 2018
Cancer Type: Skin, Basal Cell     
Intent: Curative, Palliative
Funding:
Exceptional Access Program
    vismodegib - Treatment for metastatic basal cell carcinoma (BCC) or with locally advanced BCC (including patients with basal cell nevus syndrome, i.e. Gorlin syndrome), according to specific criteria
Jun 2019